Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 10(1): 11498, 2020 07 13.
Article in English | MEDLINE | ID: mdl-32661246

ABSTRACT

Chondrus crispus is a marine red alga with sulfated galactans, called carrageenans, in its extracellular matrix. Chondrus has a complex haplodiplontic life cycle, alternating between male and female gametophytes (n) and tetrasporophytes (2n). The Chondrus life cycle stages are isomorphic; however, a major phenotypic difference is that carrageenan composition varies significantly between the tetrasporophytes (mainly lambda-carrageenan) and the gametophytes (mainly kappa/iota-carrageenans). The disparity in carrageenan structures, which confer different chemical properties, strongly suggests differential regulation of carrageenan-active genes between the phases of the Chondrus life cycles. We used a combination of taxonomy, biochemistry and molecular biology to characterize the tetrasporophytes and male and female gametophytes from Chondrus individuals isolated from the rocky seashore off the northern coast of France. Transcriptomic analyses reveal differential gene expression of genes encoding several galactose-sulfurylases, carbohydrate-sulfotransferases, glycosyltransferases, and one family 16 glycoside hydrolase. Differential expression of carrageenan-related genes was found primarily between gametophytes and tetrasporophytes, but also between the male and female gametophytes. The differential expression of these multigenic genes provides a rare glimpse into cell wall biosynthesis in algae. Furthermore, it strongly supports that carrageenan metabolism holds an important role in the physiological differentiation between the isomorphic life cycle stages of Chondrus.


Subject(s)
Carrageenan/genetics , Chondrus/genetics , Receptors, Immunologic/genetics , Animals , Carrageenan/metabolism , Chondrus/growth & development , Galactose/genetics , Gene Expression Regulation, Developmental/genetics , Germ Cells, Plant/growth & development , Germ Cells, Plant/metabolism , Life Cycle Stages/genetics
2.
Mar Drugs ; 13(4): 2250-66, 2015 Apr 14.
Article in English | MEDLINE | ID: mdl-25874922

ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative disorder in the elderly people, currently with no cure. Its mechanisms are not well understood, thus studies targeting cause-directed therapy or prevention are needed. This study uses the transgenic Caenorhabditis elegans PD model. We demonstrated that dietary supplementation of the worms with an extract from the cultivated red seaweed Chondrus crispus decreased the accumulation of α-synulein and protected the worms from the neuronal toxin-, 6-OHDA, induced dopaminergic neurodegeneration. These effects were associated with a corrected slowness of movement. We also showed that the enhancement of oxidative stress tolerance and an up-regulation of the stress response genes, sod-3 and skn-1, may have served as the molecular mechanism for the C. crispus-extract-mediated protection against PD pathology. Altogether, apart from its potential as a functional food, the tested red seaweed, C. crispus, might find promising pharmaceutical applications for the development of potential novel anti-neurodegenerative drugs for humans.


Subject(s)
Chondrus/chemistry , Dietary Supplements , Neuroprotective Agents/therapeutic use , Parkinson Disease/diet therapy , Plant Extracts/therapeutic use , Seaweed/chemistry , alpha-Synuclein/antagonists & inhibitors , Animals , Animals, Genetically Modified , Aquaculture , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Behavior, Animal/drug effects , Caenorhabditis elegans , Caenorhabditis elegans Proteins/agonists , Caenorhabditis elegans Proteins/antagonists & inhibitors , Caenorhabditis elegans Proteins/genetics , Caenorhabditis elegans Proteins/metabolism , Chondrus/growth & development , Disease Models, Animal , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/pathology , Humans , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Microscopy, Fluorescence , Movement/drug effects , Neuroprotective Agents/administration & dosage , Neurotoxins/antagonists & inhibitors , Neurotoxins/toxicity , Oxidative Stress/drug effects , Parkinson Disease/metabolism , Parkinson Disease/pathology , Plant Extracts/administration & dosage , Recombinant Fusion Proteins/metabolism , Seaweed/growth & development , alpha-Synuclein/genetics , alpha-Synuclein/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...